300639 Stock Overview
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Guangdong Hybribio Biotech Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥6.96 |
52 Week High | CN¥11.91 |
52 Week Low | CN¥5.65 |
Beta | 0.48 |
1 Month Change | -5.82% |
3 Month Change | -24.76% |
1 Year Change | -39.23% |
3 Year Change | -42.19% |
5 Year Change | 11.98% |
Change since IPO | 77.62% |
Recent News & Updates
Recent updates
Shareholder Returns
300639 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -7.8% | -4.9% | -2.2% |
1Y | -39.2% | -20.7% | -14.8% |
Return vs Industry: 300639 underperformed the CN Biotechs industry which returned -20.7% over the past year.
Return vs Market: 300639 underperformed the CN Market which returned -14.8% over the past year.
Price Volatility
300639 volatility | |
---|---|
300639 Average Weekly Movement | 6.8% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 8.1% |
10% most volatile stocks in CN Market | 11.4% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 300639's share price has been volatile over the past 3 months.
Volatility Over Time: 300639's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 2,733 | Jianyu Wang | https://www.hybribio.cn |
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.
Guangdong Hybribio Biotech Co.,Ltd. Fundamentals Summary
300639 fundamental statistics | |
---|---|
Market cap | CN¥4.45b |
Earnings (TTM) | CN¥409.39m |
Revenue (TTM) | CN¥2.19b |
10.9x
P/E Ratio2.0x
P/S RatioIs 300639 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300639 income statement (TTM) | |
---|---|
Revenue | CN¥2.19b |
Cost of Revenue | CN¥787.65m |
Gross Profit | CN¥1.40b |
Other Expenses | CN¥991.97m |
Earnings | CN¥409.39m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 24, 2024
Earnings per share (EPS) | 0.64 |
Gross Margin | 64.02% |
Net Profit Margin | 18.70% |
Debt/Equity Ratio | 1.7% |
How did 300639 perform over the long term?
See historical performance and comparison